



METASTATIC CLEAR CELL RENAL CELL CARCINOMA: How to navigate among multiple options and RISK groups? What is the best sequence in a Multi-line setting?

HALL 7 CORDOBA AUDITORIUM

BARCELONA, SPAIN

Chairs

Bernard Escudier, France Manuela Schmidinger, Austria

This educational activity is provided by ESMO and supported by Ipsen.



SUNDAY, 29 SEPTEMBER 2019 18:30 – 20:00

18:30 Introduction Bernard Escudier, Villejuif, France 18:35 Present standard of care according to the 2019 **ESMO** Guidelines Manuela Schmidinger, Vienna, Austria Comparative outcome in first-line according to 18:55 prognostic group and criteria for decision making Camillo Porta, Pavia, Italy 19:15 Options and criteria for treatment choice in second- and third- lines Ronald de Wit, Rotterdam, Netherlands How to sequence the use of drugs in a multi-lines' 19:35 strategy for RCC?

Bernard Escudier, Villejuif, France



